CN-119837120-B - Compound medicine based on Serratia marcescens for preventing termites

Abstract

The invention provides a compound medicament for preventing termites based on Serratia marcescens, which comprises Serratia marcescens of 7.75X10 8 ～2.63×10 12 CFU/mL, and pathogenic fungi or biological source pesticide or insect growth regulator or chemical agent, wherein the pathogenic fungi are beauveria bassiana or metarhizium anisopliae, the biological source pesticide is ivermectin, the insect growth regulator is lufenuron or buprofezin or antifeedant hydrazine, and the chemical agent is emamectin or indoxacarb. The compound medicament has obvious synergistic effect on termite control, reduces the use amount of a single medicament, and has lower cost, higher efficiency, stability and greenness.

Inventors

• TANG FANG
• Zhou Yujingyun
• FANG YONGFU
• XIONG YAN

Assignees

• 南京林业大学

Dates

Publication Date

20260512

Application Date

20250113

Claims (3)

1. 1. The compound medicament for preventing and controlling termites based on Serratia marcescens is characterized in that the compound medicament composition is Serratia marcescens and ivermectin, the Serratia marcescens concentration is 7.75X10 8 CFU/mL, the ivermectin concentration is 0.01 mg/mL, and the compound volume ratio is 5:1 or 1:5 or 1:9.
2. 2. The compound medicament for preventing and controlling termites based on Serratia marcescens is characterized in that the compound medicament is prepared by compounding Serratia marcescens with ivermectin with the volume ratio of 8.75X10 10 CFU/mL and ivermectin with the volume ratio of 0.05 mg/mL, and the compound volume ratio is 2:1 or 1:1 or 1:2.
3. 3. The compound medicament according to claim 1 or 2, wherein the termites are subterranean termites or subterranean termites.

Description

Compound medicine based on Serratia marcescens for preventing termites Technical Field The invention belongs to the field of termite control, and in particular relates to a compound medicament for controlling termite based on Serratia marcescens. Background Termites are a well known social insect that typically cause considerable damage to buildings, agriculture and forestry crops, standing trees and forests, earth dams in reservoirs, etc. by feeding on substances composed of cellulose, causing significant losses to humans (Su and scheffrahn, 2000; wang et al, 2018, chiu et al, 2022). Therefore, the search for safe and efficient agents is a direction of consideration for termite control. Serratia marcescens (SERRATIA MARCESENS) is ubiquitous in laboratory rearing and field-harvested insects and has pathogenic effects on many insects, including orthoptera, homoptera, lepidoptera, and the like (Nehme et al.2007, niu et al 2015, AGGARWAL ET al 2017). Studies have shown that Serratia marcescens (SM 1) has good application prospects in biological control of pests (Bidari et al, 2017;Atanakul et al, 2020; zhao et al, 2020). Our previous studies also showed that Serratia marcescens has better control of subterranean termites (Fu et al, 2021;Wang etal.2024). Therefore, the Serratia marcescens has great application prospect in pest control. Besides being capable of being directly used as biological agent to control pests, the insect pathogen can also be used as a biological synergist of chemical pesticides or insect growth regulators and the like. Insect pathogens, chemical pesticides, insect growth regulators, biogenic pesticides and pathogenic fungi have various advantages, making their combined use a good approach to solving many pest problems (Paula et al, 2011). Disclosure of Invention The invention aims to obtain a compound medicament which is more green and efficient for controlling termites by controlling termites through the combination of Serratia marcescens and different types of pesticides. In order to achieve the above purpose, the present invention provides the following technical solutions: The invention provides a compound medicament for preventing and controlling termites based on Serratia marcescens, wherein the compound medicament composition comprises Serratia marcescens, and an insect growth regulator or pathogenic fungi or biological source pesticide or chemical agent; The insect growth regulator is lufenuron or buprofezin or antifeedant hydrazine; The pathogenic fungi are beauveria bassiana or metarhizium anisopliae; the biological source pesticide is ivermectin; the chemical agent is ivermectin or emamectin benzoate or indoxacarb; The bacterial load of Serratia marcescens is 7.75X10 8～2.63×1012 CFU/mL; the pathogenic fungi is 2X 10 8 Conidia/mL; the ivermectin is 0.01-0.05 mg/mL; The concentration of the insect growth regulator is 1-5.11 mg/mL; the concentration of the chemical agent is 0.01-0.02 mg/mL. Further, when the compound drug composition is composed of Serratia marcescens and buprofezin, the Serratia marcescens is 7.75X10 8～8.75×1010 CFU/mL, the buprofezin is 1 mg/mL-10 -2 mol/L in concentration, namely the concentration ratio is 1-3.05 mg/mL, and the compound volume ratio is 9:1-1:2. When the compound drug composition is Serratia marcescens and pathogenic fungi, the Serratia marcescens is 2.63 multiplied by 10 12 CFU/mL, the pathogenic fungi is 2 multiplied by 10 8 Conidia/mL, and the compound volume ratio is 2:1-1:2. When the compound medicine composition is Serratia marcescens and hydrazine inhibitor, the Serratia marcescens is 7.75X10 8 CFU/mL, the hydrazine inhibitor is 1mg/mL, and the compound volume ratio is 5:1-1:9. When the compound drug composition is Serratia marcescens and lufenuron, the Serratia marcescens is 8.75X10 10 CFU/mL, the lufenuron concentration is 10 -2 mol/L (5.11 mg/mL), and the compound volume ratio is 2:1-1:2. When the compound drug composition is Serratia marcescens and emamectin benzoate or indoxacarb, the Serratia marcescens is 7.75X10 8 CFU/mL, the emamectin benzoate concentration is 0.02mg/mL, the indoxacarb concentration is 0.01mg/mL, and the compound volume ratio of Serratia marcescens to emamectin benzoate or indoxacarb is 5:1-1:9. When the compound medicament is prepared from Serratia marcescens of 7.75X10 8 CFU/mL and ivermectin of 0.01mg/mL, the volume ratio is 5:1-1:9. When the compound medicine is prepared by 8.75X10 10 CFU/mL Serratia marcescens and 5.7X10 -5 mol/L (0.05 mg/mL) ivermectin, the volume ratio is 2:1-1:2. Further, the compound volume ratio of Serratia marcescens to buprofezin is 1:1. Further, the termites are black wing subterranean termites or black chest subterranean termites. The invention has the beneficial effects that: (1) The Serratia marcescens can be compounded with other low-toxicity and low-residue medicaments for use, so that the insecticidal time can be shortened, the stability can be improved, the control effect can